Study on Carboplatin with or without Nivolumab for Treating Metastatic Triple Negative Breast Cancer

Inclusion Criteria

• Must have confirmed invasive breast cancer that cannot be surgically removed and has spread to other parts of the body.
• Cancer must be triple-negative, meaning low levels of estrogen and progesterone receptors and HER2-negative.
• Must have PD-L1 status available from a certified lab test.
• Must have measurable or evaluable disease based on specific criteria.
• Must agree to provide a tumor sample for research purposes, if safely accessible.
• Must not have received prior chemotherapy for metastatic breast cancer.
• Must be 18 years or older.
• Must have good overall health with normal organ and marrow function.
• Women of childbearing potential must have a negative pregnancy test and agree to use effective contraception during and after the study.
• Men must agree to use contraception during and after the study.
• Must be able to understand and agree to the study requirements.

Exclusion Criteria

• Cannot receive other anti-cancer treatments during the study.
• Cannot have allergies to platinum chemotherapy or Nivolumab.
• Cannot have untreated or symptomatic brain metastases.
• Cannot have had major surgery within two weeks before joining the study.
• Cannot have uncontrolled illnesses or infections.
• Cannot require chronic steroid or immunosuppressive therapy.
• Cannot have a history of autoimmune diseases requiring treatment.
• Cannot have active lung diseases like pneumonitis.
• Cannot have had another cancer within the last three years, except for certain low-risk cancers.
• Cannot be HIV positive or have active hepatitis B or C.
• Cannot have received a live vaccine within 28 days before joining the study.
• Cannot be pregnant or breastfeeding.